Hexarelin Acetate

1mg Vial

5mg Vial

2 September 2026Updated 2 September 2026

Hexarelin Acetate

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Hexarelin Acetate.

Create free account Member login

Full range of benefits for Hexarelin Acetate

Stimulates pulsatile growth hormone release via GHS‑R1a agonism

Raises circulating IGF‑1 levels secondarily to GH stimulation

May support lean mass gains and body composition improvements

Can produce orexigenic (appetite‑stimulating) effects

Shows cardioprotective effects in preclinical models (improved function)

May reduce myocardial apoptosis and fibrosis in animal studies

Potential to aid muscle recovery and strength via anabolic pathways

May positively influence bone metabolism through GH/IGF‑1 signaling

Used experimentally as a diagnostic GH secretagogue challenge

Exhibits anti‑inflammatory/antioxidant effects in cardiac tissues (preclinical)

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(3)Compatible(4)Monitor(4)Avoid(4)

Use with professional oversight

Insulin and oral hypoglycemic agents

GH stimulation can induce insulin resistance and hyperglycaemia, so blood glucose and antidiabetic dosing should be monitored and adjusted as needed.

Somatostatin analogs (e.g., octreotide)

Somatostatin analogs suppress GH secretion and can blunt hexarelin efficacy, requiring monitoring of GH/IGF‑1 response and potential timing adjustments.

Systemic glucocorticoids

Glucocorticoids antagonize the GH axis and metabolic effects of hexarelin, necessitating monitoring of therapeutic response and metabolic parameters.

Thyroid hormone replacement (levothyroxine)

GH-axis modulation can alter peripheral thyroid hormone metabolism, so thyroid function tests and clinical status should be monitored during co-administration.

All interaction categories

Synergistic (3)

GHRH analogs (e.g., sermorelin): Co-administration with GHRH analogs produces additive GH release by engaging complementary hypothalamic/pituitary pathways (GHRH and GHS-R1a).
Resistance exercise: Acute resistance exercise potentiates GH secretion induced by hexarelin and enhances downstream anabolic and metabolic adaptations.
Protein/leucine-rich nutritional supplementation: Adequate dietary protein and leucine support anabolic signaling and can augment the IGF-1–mediated effects of GH released in response to hexarelin.

Compatible (4)

Statins (HMG-CoA reductase inhibitors): No known direct pharmacodynamic or pharmacokinetic interaction with hexarelin; statin therapy is generally compatible without dose adjustment.
ACE inhibitors / ARBs: Renin–angiotensin system blockers have no established interaction with hexarelin and can be co‑administered with routine clinical monitoring.
Topical dermatologic agents: Locally applied dermatologic medications have no systemic interaction with hexarelin and are compatible with peptide therapy.
Multivitamin/mineral supplementation (including vitamin D): Standard vitamin and mineral supplements do not interact with hexarelin and are compatible as supportive nutritional therapy.

Monitor (4)

Insulin and oral hypoglycemic agents: GH stimulation can induce insulin resistance and hyperglycaemia, so blood glucose and antidiabetic dosing should be monitored and adjusted as needed.
Somatostatin analogs (e.g., octreotide): Somatostatin analogs suppress GH secretion and can blunt hexarelin efficacy, requiring monitoring of GH/IGF‑1 response and potential timing adjustments.
Systemic glucocorticoids: Glucocorticoids antagonize the GH axis and metabolic effects of hexarelin, necessitating monitoring of therapeutic response and metabolic parameters.
Thyroid hormone replacement (levothyroxine): GH-axis modulation can alter peripheral thyroid hormone metabolism, so thyroid function tests and clinical status should be monitored during co-administration.

Avoid (4)

Active malignancy or history of GH/IGF‑1–sensitive tumors: Because GH/IGF‑1 signaling can potentially promote tumor growth, avoid or use hexarelin only after oncologic evaluation and clearance.
Pregnancy and lactation: Safety of hexarelin in pregnancy and breastfeeding is not established, so use is not recommended unless potential benefit justifies potential risk.
Pre-existing cardiovascular disease (ischemic heart disease, uncontrolled hypertension, arrhythmias): Hexarelin has cardiovascular effects and may alter hemodynamics, so assess risk–benefit and monitor cardiac status closely when used in these patients.
Concurrent recombinant human growth hormone (rhGH) therapy: Combining rhGH with a GH secretagogue increases the risk of GH excess and adverse metabolic effects, so necessity should be reviewed and IGF‑1 and clinical markers monitored.